Key Developments: AngioDynamics Inc (ANGO.O)

ANGO.O on Nasdaq

14.10USD
22 Aug 2014
Price Change (% chg)

$-0.08 (-0.56%)
Prev Close
$14.18
Open
$14.10
Day's High
$14.25
Day's Low
$13.98
Volume
56,479
Avg. Vol
107,929
52-wk High
$19.00
52-wk Low
$10.84

Search Stocks

Latest Key Developments (Source: Significant Developments)

AngioDynamics Inc gives Q1, FY 2015 guidance; EPS guidance above analysts' estimates
Wednesday, 23 Jul 2014 04:01pm EDT 

AngioDynamics Inc:Expects FY 2015 range of $362 million to $368 million in revenue.Expects FY 2015 adjusted earnings per share (EPS), of $0.64-$0.70.Anticipates revenue to range from $83 million to $86 million in Q1 2015.Anticipates EPS to be in the range of $0.08-$0.12 in Q1 2015.Q1 2015 revenue of $85 million and EPS of $0.06 - Thomson Reuters I/B/E/S.FY 2015 revenue of $367 million and EPS of $0.40 - Thomson Reuters I/B/E/S.  Full Article

Angiodynamics receives Novation Innovative Technology Contract
Monday, 21 Jul 2014 06:30am EDT 

AngioDynamics Inc:Receives an Innovative Technology Contract for the company's BioFlo PICC and BioFlo Port products from Novation.  Full Article

Angiodynamics Inc announces FDA clearance for Celerity Tip Location System
Wednesday, 18 Jun 2014 06:29am EDT 

Angiodynamics Inc:U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Celerity tip location system.Celerity System has been cleared by FDA as adjunct to aid in positioning Peripherally Inserted Central Catheters (PICCs) in adults by providing real time catheter tip location utilizing the patient's cardiac electrical activity.Company expects to begin U.S. distribution in early July.  Full Article

Angiodynamics Inc names Howard W. Donnelly Chairman of Board
Tuesday, 29 Apr 2014 06:30am EDT 

Angiodynamics Inc:Appoints Howard W. Donnelly as Chairman of the Board effective immediately.  Full Article

Angiodynamics Inc raises FY 2014 revenue guidance; lowers FY 2014 EPS guidance; gives Q4 2014 guidance; EPS guidance above analysts' estimates
Wednesday, 9 Apr 2014 04:01pm EDT 

Angiodynamics Inc:Raises FY 2014 sales guidance to a range of $351 million to $355 million.Revises FY 2014 adjusted EPS without amortization to a range of $0.60 to $0.63 due to current product and geographic mix, as well as unanticipated costs related to the recent Medcomp agreement.Expects Q4 2014 revenue to range from $91 million to $95 million.Expects Q4 2014 adjusted EPS without amortization to be in the range of $0.18-$0.21.FY 2014 revenue of $352 million and EPS of $0.33 - Thomson Reuters I/B/E/S.Q4 2014 revenue of $93 million and EPS of $0.14 - Thomson Reuters I/B/E/S.  Full Article

Angiodynamics Inc receives $74.9 mln in case against biolitec AG
Thursday, 20 Mar 2014 06:30am EDT 

Angiodynamics Inc:Recent court action in its legal case against biolitec AG.On March 18, United States District Court for District of Massachusetts entere judgment awarding AngioDynamics $74.9 mlnin damages based on AngioDynamics.Claims that biolitec AG, Biomed Technology Holdings Limited and Wolfgang Neuberger tortiously interfered with its U.S. subsidiary, biolitec Inc.'s, contractual obligations.Judgment is also based on claims of piercing the biolitec's corporate veil, fraudulent transfers and violations of Massachusetts's Unfair Business Practices Act.Dispute originally began when AngioDynamics asserted biolitec Inc. breached contractual agreement to defend and indemnify AngioDynamics against patent infringement claims by third parties arising out of use of laser vein ablation products supplied by biolitec.  Full Article

Angiodynamics Inc receives expanded FDA clearance for AngioVac
Tuesday, 11 Mar 2014 06:30am EDT 

Angiodynamics Inc:U.S. Food and Drug Administration (FDA) cleared expanded indication for AngioVac cannula for venous drainage during extracorporeal bypass for up to six hours to include removal of fresh, soft thrombi or emboli.AngioVac cannula and circuit, when combined with other manufacturers' filters, pumps and return cannula, comprise extracorporeal bypass circuit that facilitates drainage, filtration and reinfusion of blood for up to six hours.  Full Article

AngioDynamics, Inc announces retirement of chairman - Form 8-K
Monday, 10 Mar 2014 04:45pm EDT 

AngioDynamics, Inc:Says Vincent A. Bucci, non-executive Chairman, delivered notice of his retirement from the Board, effective immediately.  Full Article

Angiodynamics Inc receives FDA clearance for DuraMax Dialysis Catheter with BioFlo Technology to reduce Catheter-Related Thrombus
Friday, 7 Mar 2014 06:30am EST 

Angiodynamics Inc:U.S. Food and Drug Administration granted 510(k) clearance for its BioFlo DuraMax chronic hemodialysis catheter.This marks third U.S. clearance of BioFlo product line in company's Vascular Access business.Indicated for use in attaining long-term vascular access for hemodialysis and apheresis, AngioDynamics expects a commercial launch in fourth quarter of fiscal year 2014.  Full Article

Angiodynamics Inc raises low end of prior FY 2014 revenue guidance; reaffirms FY 2014 EPS guidance; Q3 2014 guidance; EPS guidance above analysts' estimates
Thursday, 9 Jan 2014 04:05pm EST 

Angiodynamics Inc:Says as a result of stronger than anticipated H1 2014.Says for FY 2014 it is raising the low end of revenue guidance to $349 million to $353 million.Says for FY 2014 it expect to report adjusted EPS, excluding amortization, of $0.63 to $0.67 per share, which is consistent with its prior guidance.Says Q3 2014 revenue to range from $85 million to $88 million.Says Q3 2014 adjusted EPS, excluding amortization, is expected to be $0.15 to $0.18 per share.Q3 2014 revenue of $86 million and EPS of $0.10 - Thomson Reuters I/B/E/S Estimates.FY 2014 revenue of $351 million - Thomson Reuters I/B/E/S Estimates.  Full Article

Search Stocks